iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
Long-Acting HIV PrEP & Treatment for Women & Men
/ Once A Month or 8 Weeks Injection
 
 
  Download the PDF
 
Long acting injectable Cabotegravir for PrEP is in Phase 3 [every 4 or 8 weeks] so this is the closest in terms of reality, for a major impact of long-acting drugs with a potential to impact HIV & AIDS, but in the area of PrEP. Increasingly over the past few years we have been hearing about nano technology and about implants which would be long acting and have the added characteristic that the implant could be removed at any time, this helps regarding if adverse events occur related to the drug in question.
 
HPTN 083 & HPTN 084 [for women]..... https://www.hptn.org/research/studies/176 https://www.niaid.nih.gov/news-events/nih-launches-first-large-trial-long-acting-injectable-drug-hiv-prevention A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men.....https://www.hptn.org/sites/default/files/2016-06/(T5) Raphael Landovitz - FINAL v2 (6.14.2016)_0.pdf
 
IAS: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
 
IAS:
Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17)

1002171

IAS:
Long-Acting 4/8-Week Cabotegravir/Rilpivirine Maintains Control at 96 Weeks - Mark Mascolini - (07/23/17)
 
Satisfaction, Tolerability, and Acceptability of Cabotegravir (CAB) + Rilpivirine (RPV) Long-Acting Therapy: LATTE-2 Results - (07/29/16)

1002172

-----------------
 
Long term antiretroviral injection proves effective in trial

 
"A long acting injection for HIV could transform antiretroviral therapy (ART) for patients who struggle to take a daily pill....The injection, which had extremely high patient satisfaction"
 
BMJ 2017
 
(Published 24 July 2017)
 
A long acting injection for HIV could transform antiretroviral therapy (ART) for patients who struggle to take a daily pill, a leading doctor has said, after the first study of a fully injectable antiretroviral regimen found it to be effective.
 
Research presented at the International AIDS Society's Conference on HIV Science in Paris, France, showed that a four or eight week maintenance ART injection of cabotegravir plus rilpivirine had high rates of virologic response and was well tolerated through 96 weeks. At the end of a two year trial of 286 people, 94% of patients who had received the eight week injection and 87% of those who had the four week injection had the virus under control, defined as having fewer than 50 copies of the virus per millilitre of blood. This compared with 84% of patients who continued with oral treatment.
 
Patients were recruited from the US and Europe and were virologically suppressed with oral treatment for 20 weeks.
 
The study has moved into phase III registration trials with the aim of the monthly injection, rather than the eight week injection, being approved when the trials are completed next year. The injection, which had extremely high patient satisfaction, is intramuscular and must be administered in a healthcare setting.
 
Joseph Eron, professor of medicine at the University of North Carolina, USA, and lead author of the study, told The BMJ that, despite "terrific" oral treatments for HIV, the injection had the potential to reach patients who struggle to take a pill each day. "People with chaotic lives, people who have difficulty with adherence, and people with substance misuse or mental health illness may be able to take advantage of this long acting therapy," said Eron, adding that it could also be hugely beneficial for adolescents.
 
"A lot of people who were in the study appreciated not having to take a pill every day. Not only because you have to remember it and you might forget but [because] patients feel kind of free from that daily reminder that they have HIV," he said.
 
Linda-Gail Bekker, deputy director of the Desmond Tutu HIV Centre in Cape Town, South Africa, said that new treatment options would "bring us a step closer to seeing the end of this epidemic."
 
Long acting injectable Cabotegravir for PrEP is in Phase 3 [every 4 or 8 weeks] so this is the closest in terms of reality, for a major impact of long-acting drugs with a potential to impact HIV & AIDS, but in the area of PrEP. Increasingly over the past few years we have been hearing about nano technology and about implants which would be long acting and have the added characteristic that the implant could be removed at any time, this helps regarding if adverse events occur related to the drug in question.
 
HPTN 083 & HPTN 084 [for women]..... https://www.hptn.org/research/studies/176 https://www.niaid.nih.gov/news-events/nih-launches-first-large-trial-long-acting-injectable-drug-hiv-prevention A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men..... https://www.hptn.org/sites/default/files/2016-06/(T5) Raphael Landovitz - FINAL v2 (6.14.2016)_0.pdf
 
CROI: A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY - (02/23/17)
 
CROI: Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy - (02/18/17)
 
CROI2016: ECLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men.......Long-Acting Cabotegravir Data Suggest PrEP Injections Every 8 Week
 
CROI: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir - (02/29/16)
 
CROI: Long Acting HIV ART - is this the future? Nanoformulations - Implants - (03/02/17)
 
Long-Acting & Nanoparticle ARTs - Future of HIV Medication??? - (03/22/17)

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org